Drug is no longer a research priority; resources should focus on other more promising drugs to prevent covid-19
World health organization experts have strongly issued warning against the use of hydroxychloroquine on patients who are not affected with the Coronavirus.
The warning is coming as a result of evidence from six randomised controlled trials involving over 6,000 participants with and without known exposure to a person with covid-19 infection.
According to WHO, the “evidence showed that hydroxychloroquine had no meaningful effect on death and admission to hospital, while moderate certainty evidence showed that hydroxychloroquine had no meaningful effect on laboratory confirmed covid-19 infection and it probably increases the risk of adverse effects”.
It is against this backdrop that the panel said that the hydroxychloroquine drug is no longer a research priority and that resources should be channeled towards evaluating other more promising drugs to prevent covid-19.
According to WHO “the guideline applies to all individuals who do not have the virus regardless of their exposure to a person with covid-19 infection.
The panel judged that almost all people would not consider this drug worthwhile, and also decided that factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation.
The recommendation is the first version of a living guideline for drugs to prevent covid-19, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation.
The aim of this guidelines is to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with patients.